Paul Scigalla - Jan 25, 2023 Form 3 Insider Report for GENELUX CORP (GNLX)

Role
Chief Medical Officer
Signature
/s/ Sean Ryder, J.D., Attorney-in-Fact
Stock symbol
GNLX
Transactions as of
Jan 25, 2023
Transactions value $
$0
Form type
3
Date filed
1/25/2023, 06:25 PM
Next filing
Oct 21, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding GNLX Stock Option (right to buy) Jan 25, 2023 Common Stock 30.6K $9.00 Direct F1
holding GNLX Stock Option (right to buy) Jan 25, 2023 Common Stock 16.7K $9.00 Direct F1
holding GNLX Stock Option (right to buy) Jan 25, 2023 Common Stock 16.7K $9.00 Direct F1
holding GNLX Stock Option (right to buy) Jan 25, 2023 Common Stock 16.7K $9.00 Direct F1
holding GNLX Stock Option (right to buy) Jan 25, 2023 Common Stock 16.7K $9.00 Direct F1
holding GNLX Stock Option (right to buy) Jan 25, 2023 Common Stock 16.7K $9.00 Direct F1
holding GNLX Stock Option (right to buy) Jan 25, 2023 Common Stock 16.7K $9.00 Direct F1
holding GNLX Stock Option (right to buy) Jan 25, 2023 Common Stock 16.7K $9.00 Direct F1
holding GNLX Stock Option (right to buy) Jan 25, 2023 Common Stock 16.7K $9.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Immediately exercisable.